Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Nitrate/nitrate derivatives vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 77 participants
GRADE not reported

Nitrate/nitrate derivatives vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nitrate/nitrate derivatives vs placebo

Adverse events (3 weeks' · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8 participants
GRADE not reported

Nitrate/nitrate derivatives vs placebo

RCS · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 69 participants
Low

Phosphodiesterase inhibitors vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Low

Phosphodiesterase inhibitors vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Very low

Phosphodiesterase inhibitors vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

Adverse events · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 138 participants
GRADE not reported

Phosphodiesterase inhibitors vs placebo

RCS · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

Adverse events (4 to 6‐week · primary Raynaud's phenomenon

Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.35 [0.67, 2.73]
3 studies · 46 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alpha‐blockers vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Alpha‐blockers vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
GRADE not reported

Alpha‐blockers vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Heliox vs placebo or no treatment

Change in croup score. · children with croup

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Low

Heliox vs placebo or no treatment

Change in respiratory rate at 20 minutes · children with croup

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Low

Heliox vs placebo or no treatment

Change** in heart rate (beats/min) · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Proportion of children hospitalised · children with croup

Heliox showed no clear difference in proportion of children hospitalised compared with placebo or no treatment (low certainty).

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
OR 0.46 [0.04, 5.41]
1 study · 47 participants
Low